Guangzhou LBP Medicine Science & Technology Co., Ltd. Share Price

Equities

688393

CNE1000043R4

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 23:00:00 13/05/2024 BST 5-day change 1st Jan Change
18.19 CNY +0.94% Intraday chart for Guangzhou LBP Medicine Science & Technology Co., Ltd. -5.26% -27.15%

Financials

Sales 2022 507M 70.15M 5.57B Sales 2023 497M 68.76M 5.46B Capitalization 2.34B 323M 25.66B
Net income 2022 42M 5.81M 461M Net income 2023 40M 5.53M 439M EV / Sales 2022 3.57 x
Net cash position 2022 242M 33.41M 2.65B Net cash position 2023 91.86M 12.7M 1.01B EV / Sales 2023 4.51 x
P/E ratio 2022
48.9 x
P/E ratio 2023
59.5 x
Employees -
Yield 2022
0.64%
Yield 2023
-
Free-Float 43.15%
More Fundamentals * Assessed data
Dynamic Chart
Chinese Drug Regulator Grants Certificates to Two LBP Medicine Science & Technology Products MT
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
LBP Medicine Scraps Convertible Bonds Issuance Plans MT
LBP Medicine Gets Certificate for HER2 Antibody Reagent MT
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A Shares of LBP Medicine Science & Technology Co., Ltd are subject to a Lock-Up Agreement Ending on 20-AUG-2023. CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
More news
1 day+0.94%
1 week-5.26%
Current month-3.24%
1 month+1.22%
3 months+17.51%
6 months-30.49%
Current year-27.15%
More quotes
1 week
17.92
Extreme 17.92
19.76
1 month
15.30
Extreme 15.3
19.76
Current year
12.83
Extreme 12.83
25.85
1 year
12.83
Extreme 12.83
34.48
3 years
12.83
Extreme 12.83
41.33
5 years
12.83
Extreme 12.83
74.00
10 years
12.83
Extreme 12.83
74.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 05/07/05
Director of Finance/CFO 41 15/05/22
Chief Administrative Officer 44 30/06/07
Members of the board TitleAgeSince
Chief Executive Officer 59 05/07/05
Director/Board Member 43 19/11/17
Director/Board Member 47 31/10/05
More insiders
Date Price Change Volume
13/05/24 18.19 +0.94% 635 186
13/05/24 18.02 -5.65% 1,375,334
10/05/24 19.1 -2.55% 632,427
09/05/24 19.6 +4.03% 1,252,468
08/05/24 18.84 -2.13% 852,193

End-of-day quote Shanghai S.E., May 13, 2024

More quotes
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 688393 Stock